Global Leprosy Treatment Market Overview:
Leprosy is a disease caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis, which causes granulomas in the nerves, respiratory tract, and other organs. Granulomas can cause a loss of pain perception, particularly in the extremities, such as the finger tips. The nerves, skin, eyes, mucosa (of the mouth, nose, and pharynx), kidneys, testes, reticulo-endothelial system, and voluntary smooth muscles of the human body are the most affected. Leprosy symptoms are easy to recognize. Skin lesions with no feeling, as well as thickened or damaged nerves, are examples. Paucibacillary leprosy and multibacillary leprosy are the two types of leprosy. Some of the players profiled in the study are Glaxo Smithcline (United Kingdom), Cadila Pharmaceuticals (India), Acme Pharmaceuticals (India), Indian Drugs and Pharmaceuticals (India), Novartis International AG (Switzerland), Astra Zeneca (United Kingdom), Lark Laboratories Ltd (India), GlaxoSmithKline (United Kingdom), Sanofi (France) and Apotex (Canada).
On the basis of geography, the market of Leprosy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Antibacterial will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Leprosy Type, the sub-segment i.e. Multibacillary Leprosy will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Hospitals will boost the Leprosy Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Growth Drivers
- Favorable Government Initiatives
- Availability of Favorable Reimbursement Policies for High-Cost Therapies
- Rising Patient Pool of Leprosy in Asia-Pacific
- Low Health Care Expenditure and Least Availability of Medical Facilities for Proper Diagnosis of Leprosy Treatment
- New Treatment Options Available for Leprosy Treatment
According to WHO - The guidelines recommend a 3-drug regimen of rifampicin, dapsone and clofazimine for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and 12 months for MB leprosy.
Target Audience:Manufacturers of Leprosy Drug, Suppliers of Leprosy Drug, Wholesalers, Distributors and Retailers of Leprosy Drug, Healthcare Industry, Pharmaceutical Industry and Regulatory Bodies
Major Objectives Focused through this Study To define, describe, and forecast the Global Leprosy Treatment market on the basis of product [Borderline Tuberculoid, Tuberculoid, Borderline, Histoid and Others] , application , key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Leprosy Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Leprosy Treatment industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Macleods Pharmaceuticals (India) and Systopic Laboratories (India).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Leprosy Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.